Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | DRD4 | P21917 | 6/20 | 0.35 |
| ▸ | DRD3 | P35462 | 6/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15231070 | 0.77 | SCN5A (0.49) | SCN5ACA1CA2DRD2DRD4 | |
| SCHEMBL28422124 | 0.74 | CA1 (0.35) | CA1CA2DRD2DRD4DRD3 | |
| SCHEMBL576035 | 0.71 | CA2 (0.50) | CA1CA2DRD2DRD4DRD3 | |
| SCHEMBL18338474 | 0.71 | DRD2 (0.45) | SCN5ACA1CA2DRD2DRD4 | |
| SCHEMBL30977412 | 0.70 | RXRA (0.36) | SCN5ADRD2DRD4DRD3DRD1 | |
| SCHEMBL27037342 | 0.69 | CA1 (0.34) | CA1CA2DRD2DRD4DRD3 | |
| SCHEMBL25363072 | 0.68 | RAB9A (0.34) | DRD2DRD4DRD3PDE4APDE4C | |
| SCHEMBL20412783 | 0.68 | JAK2 (0.31) | CA1CA2PDE4APDE4CPDE4D | |
| SCHEMBL31604507 | 0.68 | CXCR2 (0.41) | CA1CA2DRD2DRD4DRD3 | |
| SCHEMBL3228819 | 0.68 | AXL (0.39) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583855-B2 | RET selective inhibitor, preparation method therefor and use thereof | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2026-03-24 | — | — | US | disclosed |
| CN-114907338-B | Nitrogen-containing polycyclic condensed ring compound, pharmaceutical composition, preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115894482-A | RET inhibitor and preparation method and application thereof | 深圳长铭医药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220289740-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-2513102-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8933094-B2 | Ethynyl compounds useful for treatment of CNS disorder | HOFFMANN-LA ROCHE INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933094-B2 | Ethynyl compounds useful for treatment of CNS disorder | HOFFMANN-LA ROCHE INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933094-B2 | Ethynyl compounds useful for treatment of CNS disorder | HOFFMANN-LA ROCHE INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140073638-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER | HOFFMANN-LA ROCHE INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073638-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER | HOFFMANN-LA ROCHE INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2565185-A1 | [5,6]HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2513102-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE, INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011073172-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073172-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583855-B2 | RET selective inhibitor, preparation method therefor and use thereof | RET, ROR1, TMPRSS11D | SCN5A 1470/4885CA1 2671/4885CA2 1103/4885 |
| US-20220289740-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | RET, REN, ROR1 | SCN5A 2133/4885CA1 2126/4885CA2 1817/4885 |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | BMP2, BMP4, SOST | SCN5A 659/4885CA1 1250/4885CA2 167/4885 |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | GRM5, GRIK5, GRM1 | SCN5A 115/4885CA1 2357/4885CA2 1167/4885 |
| US-20140073638-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER | GRM5, GRIK5, GRM1 | SCN5A 125/4885CA1 2459/4885CA2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.